Recently, Nanjing King-Friend  Biochemical Pharmaceutical Co., LTD. (hereinafter referred to as " King-Friend ") has obtained the drug registration certificate issued by the National Medical Products Administration for its Rocuronium Bromide Injection, officially approving its domestic marketing and sale.

Rocuronium Bromide Injection is an adjuvant drug for general anesthesia, used for tracheal intubation during conventional induction anesthesia and for maintaining neuromuscular block of skeletal muscles during the operation.

 King-Friend has facilitated the launch of Rocuronium Bromide Injection, aiming to continuously empower precise medication and safety management during general anesthesia, efficiently respond to the urgent clinical needs in China, and bring new hope for health to thousands of patients.